Press Releases

Press Releases2018-05-02T02:51:13-05:00

Adarza BioSystems Raises $25 Million in Series D Funding to Launch Platform for Research and Drug Development

Biotech company Adarza BioSystems announced today that it has raised $25 million in a Series D round co-led by 3x5 Partners, based in Portland, Ore., and St. Louis-based Lightchain Capital, LLC, the family office of Scottrade founder Rodger Riney. Adarza plans to use the funds to support full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. Scheduled for commercial launch in June, the ZIVA platform will allow researchers to quickly identify inflammation, cardiovascular, and oncology protein biomarkers for disease profiling and drug development.

February 4th, 2020|

Adarza BioSystems to reveal ZIVA platform at AAI 2019

Adarza Biosystems, Inc. announced today that it will reveal its new protein multiplex instrument ZIVA at Immunology 2019, the annual meeting of the American Association of Immunologists (AAI) from May 9 - 13. Using a simple, time-saving workflow, the new automated system can simultaneously measure, analyze and report on up to 200 biomarkers.

May 1st, 2019|

Adarza Sets Stage for Commercialization

Adarza Biosystems, Inc., a biotechnology company developing a novel protein and biomolecule detection platform, announced today that it has put in place the leadership, new manufacturing center and branding to begin selling its technology to researchers in the second quarter of 2019.

May 23rd, 2018|

ADARZA BIOSYSTEMS CLOSES ON $17 MILLION SERIES C FINANCING

ROCHESTER, NY and ST LOUIS, MO (Jan. 19, 2017) – Adarza BioSystems, Inc., a leading next generation innovator in label-free, multiplex assays, announced today that it has closed a $17M Series C financing. Proceeds from the financing will be used to further expand production capacity in its St. Peters, MO manufacturing facility and fund final development and commercialization of Adarza’s first immunoassay product consumable and instrument platform. Adarza develops and manufactures immunoassay technology that can identify proteins and genetic markers in medical samples such as blood. The technology, which comes in the form of microchips, helps with cancer diagnostics and allergy testing, drug and vaccine development, immunology and infectious diseases research and other applications. 3x5 RiverVest Fund II, L.P. leads the round, and RiverVest Managing Directors Dr. John [...]

January 19th, 2017|

Adarza BioSystems Completes $5 M Series-B Closing

ROCHESTER, N.Y. ST LOUIS, MO – Adarza BioSystems, Inc. a leading next generation innovator in label-free, multiplex assays announced today that it has closed a $5 M Series B financing. Proceeds from the financing will be used to expand production capacity in its St. Peters, MO manufacturing facility and launch its first immunoassay product consumable and instrument platform. Proceeds will also be used to accelerate development of highly sensitive assays targeting a variety of biological analytes including cytokines, antigens and small molecules. Adarza’s Arrayed Imaging Reflectometry (AIRstrip™) will bring an unprecedented combination of performance, workflow benefits with high sensitivity, broad dynamic range, precision, assay robustness to both life science and drug development researchers as well as clinical diagnostics practitioners . Cultivation Capital Life Science Fund, Lewis and [...]

March 24th, 2016|